The MESH CHIP project has laid a technical and conceptual foundation for a new class of spatial transcriptomics technologies that shift spatial resolution from hardware into the domain of computation. The project demonstrated key milestones such as reproducible generation of dense surface polonies, robust interlinkage chemistry for encoding spatial proximity, and reconstruction of spatial organization using only sequencing data using a computational strategy with the potential to disrupt the current industry paradigm.
The project resulted in several key technical and scientific outcomes. We successfully refined the protocols for polony generation and interlinking on functionalized surfaces, establishing a reproducible method for creating spatially informative DNA barcode networks. Using synthetic data, we demonstrated proof-of-concept spatial reconstructions with our STRND algorithm, validating the core concept of posterior localization. In parallel, we developed and submitted for revision a scientific manuscript in which we introduced spatial coherence metrics to assess the geometric integrity of DNA barcode networks, contributing foundational tools for sequencing-based microscopy. On the intellectual property front, we filed and obtained a granted Swedish patent covering the core method for generating networked 2D polony surfaces.
The potential impact of the results of this project is that we have made both technical-side and exploitation-side progress towards a viable commercial product, the MESH CHIP, that could unlock broad adoption of spatial transcriptomics in settings previously out of reach due to cost and scalability barriers. This includes high-throughput basic research (e.g. brain mapping, pharmaceutical tissue screening, clinical biopsies, and eventually routine diagnostics. By radically reducing cost per surface and eliminating the need for complex fabrication or imaging equipment, MESH CHIP could present a potential path toward spatial transcriptomics as a scalable, modular, and easily consumable solution to a wide space of domains.
The needs for further uptake and success span both technological development and commercial exploitation. On the technical side, the priority is to validate transcriptomic capture performance using biological tissue samples. In parallel, comparative benchmarking against leading spatial transcriptomics technologies like 10x Visium, Curio, etc will be necessary to quantify advantages. From an IP perspective, while a Swedish patent has been granted and a PCT application is under review, continued support is needed to navigate examiner feedback and pursue national phase entry. On the commercialization side, a startup company is being founded by the team. Pre-seed funding has been secured through KTH Innovation and KTH Holding AB, and the team is receiving guidance from a dedicated business coach. Establishing partnerships with early adopters in pharma, diagnostics, and academia will be important for validating use cases and guiding product development.